Page last updated: 2024-08-23

nedocromil and Parkinson Disease

nedocromil has been researched along with Parkinson Disease in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andersen, JK; Chinta, SJ; Rajagopalan, S	1
Andersen, JK; Beal, MF; Gwiazda, R; Lee, DW; Rajagopalan, S; Ratan, RR; Siddiq, A; Yang, L	1

Other Studies

2 other study(ies) available for nedocromil and Parkinson Disease

Article	Year
Pharmacological prolyl hydroxylase domain inhibition as a therapeutic target for Parkinson's disease. CNS & neurological disorders drug targets, 2014, Volume: 13, Issue:1 Topics: Age Factors; Analysis of Variance; Animals; Buthionine Sulfoximine; Cell Line, Transformed; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glutathione; Hydroxybenzoates; Mass Spectrometry; Mice; Mice, Transgenic; Mitochondria; Oxygen Consumption; Parkinson Disease; Prolyl Hydroxylases; Prolyl-Hydroxylase Inhibitors; Rats; Substantia Nigra	2014
Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. The Journal of biological chemistry, 2009, Oct-16, Volume: 284, Issue:42 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Gene Expression Regulation; Heme Oxygenase-1; Hydroxybenzoates; Hypoxia-Inducible Factor 1; Male; Mice; Mice, Inbred C57BL; Neurons; Oxygen; Parkinson Disease; Procollagen-Proline Dioxygenase; Rats; RNA, Messenger	2009

Article

Year

Pharmacological prolyl hydroxylase domain inhibition as a therapeutic target for Parkinson's disease.

CNS & neurological disorders drug targets, 2014, Volume: 13, Issue:1

Topics: Age Factors; Analysis of Variance; Animals; Buthionine Sulfoximine; Cell Line, Transformed; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glutathione; Hydroxybenzoates; Mass Spectrometry; Mice; Mice, Transgenic; Mitochondria; Oxygen Consumption; Parkinson Disease; Prolyl Hydroxylases; Prolyl-Hydroxylase Inhibitors; Rats; Substantia Nigra

2014

Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.

The Journal of biological chemistry, 2009, Oct-16, Volume: 284, Issue:42

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Gene Expression Regulation; Heme Oxygenase-1; Hydroxybenzoates; Hypoxia-Inducible Factor 1; Male; Mice; Mice, Inbred C57BL; Neurons; Oxygen; Parkinson Disease; Procollagen-Proline Dioxygenase; Rats; RNA, Messenger

2009